MannKind receives Breakthrough T1D grant for pediatric Afrezza trial
Go back to MannKind receives Breakthrough T1D grant for pediatric Afrezza trial| Mannkind Corporation (NASDAQ: MNKD) | Delayed: 3.89 +0.05 (1.30%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.84 | 52 Week High | $2.51 | |||
| Open | $3.73 | 52 Week Low | $0.41 | |||
| Day High | $3.91 | P/E | N/A | |||
| Day Low | $3.71 | EPS | $-0.64 | |||
| Volume | 2,935,748 | |||||
